Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Abortion, Induced | 12 | 2024 | 74 | 3.080 |
Why?
|
| Contraceptive Agents, Female | 5 | 2022 | 29 | 1.950 |
Why?
|
| Medroxyprogesterone Acetate | 3 | 2022 | 16 | 1.390 |
Why?
|
| Abortion, Legal | 3 | 2024 | 8 | 1.030 |
Why?
|
| Travel | 3 | 2024 | 116 | 1.020 |
Why?
|
| Contraception | 4 | 2023 | 58 | 0.970 |
Why?
|
| Governing Board | 1 | 2024 | 3 | 0.930 |
Why?
|
| Maternal Health Services | 1 | 2024 | 37 | 0.890 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2022 | 166 | 0.800 |
Why?
|
| Health Services Accessibility | 7 | 2024 | 606 | 0.780 |
Why?
|
| Pregnancy | 19 | 2024 | 7167 | 0.710 |
Why?
|
| Pregnancy Complications | 2 | 2024 | 507 | 0.670 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 606 | 0.620 |
Why?
|
| Ambulatory Care Facilities | 3 | 2020 | 227 | 0.550 |
Why?
|
| Abortifacient Agents | 3 | 2024 | 4 | 0.500 |
Why?
|
| Misoprostol | 3 | 2024 | 26 | 0.490 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2011 | 14 | 0.470 |
Why?
|
| Texas | 11 | 2024 | 3591 | 0.470 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 2 | 2024 | 4 | 0.450 |
Why?
|
| Reproductive Health Services | 1 | 2013 | 17 | 0.440 |
Why?
|
| Family Planning Services | 2 | 2023 | 37 | 0.410 |
Why?
|
| Abortion, Spontaneous | 2 | 2024 | 79 | 0.410 |
Why?
|
| Gynecology | 2 | 2024 | 123 | 0.390 |
Why?
|
| Ethinyl Estradiol | 1 | 2011 | 10 | 0.390 |
Why?
|
| Levonorgestrel | 1 | 2011 | 20 | 0.380 |
Why?
|
| Carbohydrate Metabolism | 1 | 2011 | 56 | 0.380 |
Why?
|
| Obstetrics | 2 | 2024 | 237 | 0.350 |
Why?
|
| Injections, Subcutaneous | 3 | 2022 | 125 | 0.340 |
Why?
|
| Female | 25 | 2024 | 66307 | 0.330 |
Why?
|
| Pregnancy in Adolescence | 1 | 2009 | 49 | 0.320 |
Why?
|
| Confidentiality | 1 | 2009 | 99 | 0.310 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 357 | 0.310 |
Why?
|
| Students, Medical | 2 | 2022 | 356 | 0.270 |
Why?
|
| Humans | 28 | 2024 | 124409 | 0.240 |
Why?
|
| Drug Implants | 3 | 2020 | 42 | 0.240 |
Why?
|
| United States | 11 | 2024 | 10775 | 0.230 |
Why?
|
| Medical Futility | 1 | 2024 | 37 | 0.230 |
Why?
|
| Travel-Related Illness | 1 | 2023 | 3 | 0.220 |
Why?
|
| Maternal Mortality | 1 | 2024 | 80 | 0.220 |
Why?
|
| Choice Behavior | 1 | 2024 | 131 | 0.220 |
Why?
|
| Patient Preference | 1 | 2024 | 119 | 0.210 |
Why?
|
| Abortifacient Agents, Steroidal | 1 | 2023 | 1 | 0.210 |
Why?
|
| Internship and Residency | 2 | 2024 | 1177 | 0.210 |
Why?
|
| Intrauterine Devices | 2 | 2013 | 14 | 0.200 |
Why?
|
| Analgesia | 1 | 2021 | 44 | 0.190 |
Why?
|
| Quality of Health Care | 1 | 2024 | 389 | 0.180 |
Why?
|
| Medicaid | 1 | 2023 | 243 | 0.180 |
Why?
|
| Desogestrel | 1 | 2020 | 6 | 0.180 |
Why?
|
| Obesity | 1 | 2011 | 2251 | 0.170 |
Why?
|
| Health Policy | 1 | 2022 | 212 | 0.170 |
Why?
|
| Adult | 9 | 2024 | 29398 | 0.160 |
Why?
|
| Young Adult | 6 | 2024 | 8979 | 0.160 |
Why?
|
| Anesthesia | 1 | 2021 | 211 | 0.150 |
Why?
|
| Consensus | 1 | 2022 | 629 | 0.150 |
Why?
|
| Mifepristone | 3 | 2024 | 135 | 0.150 |
Why?
|
| Decision Making | 1 | 2023 | 656 | 0.150 |
Why?
|
| Self Administration | 2 | 2017 | 43 | 0.150 |
Why?
|
| Education, Medical | 1 | 2022 | 287 | 0.150 |
Why?
|
| Contraception Behavior | 1 | 2017 | 26 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 161 | 0.140 |
Why?
|
| Surveys and Questionnaires | 6 | 2024 | 3735 | 0.140 |
Why?
|
| Intuition | 1 | 2017 | 5 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2020 | 377 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 579 | 0.130 |
Why?
|
| Pregnant Women | 1 | 2017 | 148 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 430 | 0.120 |
Why?
|
| Delayed-Action Preparations | 2 | 2017 | 111 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2017 | 767 | 0.120 |
Why?
|
| Feeding Behavior | 2 | 2020 | 713 | 0.120 |
Why?
|
| Eating | 1 | 2017 | 373 | 0.120 |
Why?
|
| Postpartum Period | 2 | 2020 | 216 | 0.120 |
Why?
|
| Body Mass Index | 3 | 2020 | 1550 | 0.110 |
Why?
|
| Office Visits | 1 | 2013 | 77 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2013 | 138 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2013 | 102 | 0.100 |
Why?
|
| Adolescent | 5 | 2024 | 19360 | 0.100 |
Why?
|
| Models, Biological | 1 | 2017 | 1459 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2011 | 53 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2011 | 266 | 0.090 |
Why?
|
| Contraception, Barrier | 1 | 2010 | 1 | 0.090 |
Why?
|
| Perimenopause | 1 | 2010 | 2 | 0.090 |
Why?
|
| Sterilization, Reproductive | 1 | 2010 | 4 | 0.090 |
Why?
|
| Progestins | 1 | 2010 | 48 | 0.090 |
Why?
|
| Contraceptives, Oral | 1 | 2010 | 37 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 350 | 0.080 |
Why?
|
| Patient Selection | 1 | 2013 | 688 | 0.080 |
Why?
|
| Vacuum Curettage | 1 | 2009 | 5 | 0.080 |
Why?
|
| Diet | 1 | 2017 | 1131 | 0.080 |
Why?
|
| Dilatation and Curettage | 1 | 2009 | 2 | 0.080 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2009 | 7 | 0.080 |
Why?
|
| Triglycerides | 1 | 2011 | 565 | 0.080 |
Why?
|
| Incidence | 2 | 2022 | 3086 | 0.080 |
Why?
|
| Uterine Hemorrhage | 1 | 2009 | 43 | 0.080 |
Why?
|
| Balloon Occlusion | 1 | 2009 | 47 | 0.080 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 560 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1688 | 0.070 |
Why?
|
| Parent-Child Relations | 1 | 2009 | 248 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1619 | 0.070 |
Why?
|
| Catheterization | 1 | 2009 | 236 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2011 | 1129 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2011 | 401 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2010 | 473 | 0.070 |
Why?
|
| Informed Consent | 1 | 2009 | 336 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2011 | 643 | 0.070 |
Why?
|
| Insulin | 1 | 2011 | 1207 | 0.070 |
Why?
|
| Attitude of Health Personnel | 2 | 2022 | 673 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2010 | 436 | 0.060 |
Why?
|
| Pregnancy Trimester, First | 1 | 2024 | 114 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2024 | 282 | 0.050 |
Why?
|
| Age Factors | 1 | 2010 | 2805 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2022 | 24 | 0.050 |
Why?
|
| Biomarkers | 1 | 2011 | 2980 | 0.050 |
Why?
|
| Government Regulation | 1 | 2022 | 42 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1239 | 0.050 |
Why?
|
| Perinatology | 1 | 2021 | 32 | 0.050 |
Why?
|
| Counseling | 1 | 2023 | 216 | 0.050 |
Why?
|
| Universities | 1 | 2022 | 126 | 0.050 |
Why?
|
| Forecasting | 1 | 2022 | 351 | 0.040 |
Why?
|
| Puerperal Disorders | 1 | 2020 | 46 | 0.040 |
Why?
|
| Geographic Mapping | 1 | 2020 | 14 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 398 | 0.040 |
Why?
|
| Postnatal Care | 1 | 2020 | 51 | 0.040 |
Why?
|
| Spatial Analysis | 1 | 2020 | 21 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2020 | 27 | 0.040 |
Why?
|
| Pain Management | 1 | 2021 | 181 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 150 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 1598 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2022 | 16232 | 0.040 |
Why?
|
| Pain | 1 | 2021 | 472 | 0.040 |
Why?
|
| International Planned Parenthood Federation | 1 | 2017 | 1 | 0.040 |
Why?
|
| New Jersey | 1 | 2017 | 24 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 515 | 0.040 |
Why?
|
| Rural Population | 1 | 2020 | 257 | 0.040 |
Why?
|
| Satiety Response | 1 | 2017 | 32 | 0.030 |
Why?
|
| Overweight | 1 | 2020 | 360 | 0.030 |
Why?
|
| Hunger | 1 | 2017 | 50 | 0.030 |
Why?
|
| Cues | 1 | 2017 | 90 | 0.030 |
Why?
|
| Poverty | 1 | 2020 | 418 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2017 | 239 | 0.030 |
Why?
|
| Gestational Age | 1 | 2020 | 1161 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1804 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1174 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 479 | 0.030 |
Why?
|
| Weight Gain | 1 | 2017 | 404 | 0.030 |
Why?
|
| Emotions | 1 | 2017 | 365 | 0.030 |
Why?
|
| Psychometrics | 1 | 2017 | 678 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 1005 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2875 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 6089 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2009 | 67 | 0.020 |
Why?
|
| Leucovorin | 1 | 2009 | 50 | 0.020 |
Why?
|
| Etoposide | 1 | 2009 | 117 | 0.020 |
Why?
|
| Depression | 1 | 2017 | 1248 | 0.020 |
Why?
|
| Methotrexate | 1 | 2009 | 351 | 0.020 |
Why?
|
| Male | 1 | 2024 | 61033 | 0.010 |
Why?
|